0001437749-26-009805
SEC filingLucid Diagnostics Inc. (LUCD) reported a net loss of $58.0 million for FY 2025, widening from $45.5 million in FY 2024, driven by higher operating expenses amid commercialization efforts for its EsoGuard Esophageal DNA Test. Revenue grew modestly to $4.7 million from $4.3 million YoY, reflecting increased EsoGuard test deliveries, though cost of revenue declined slightly to $6.7 million from $7.1 million. Sales and marketing expenses rose to $17.7 million from $16.5 million, supporting expanded channels like Lucid Test Centers and direct contracting. General and administrative costs increased to $23.9 million from $20.2 million, tied to higher MSA fees with PAVmed and financing activities. Research and development dipped to $5.7 million from $6.0 million. Operating cash use intensified to $46.5 million, offset by $59.0 million in financing inflows, yielding a $12.3 million cash increase to $34.7 million ending balance. Total assets stood at $40.4 million, with stockholders' equity at $10.9 million. Forward-looking, Medicare coverage pursuit and VA contract signal reimbursement potential, but going concern doubts persist due to cash burn and funding needs.
Lucid Diagnostics reported FY2025 revenue of $4.7 million, up from $4.3 million in FY2024, driven by higher EsoGuard test volumes. Net loss expanded to $58.0 million from $45.5 million YoY, reflecting increased sales/marketing ($17.7M vs $16.5M) and G&A expenses ($23.9M vs $20.2M), partially offset by lower R&D ($5.7M vs $6.0M) and cost of revenue ($6.7M vs $7.1M). Change in fair value of convertible notes added $7.7 million expense. Balance sheet shows total assets $40.4 million, cash $34.7 million, liabilities $29.5 million, equity $10.9 million. Cash flow: operating outflow $46.5 million, financing inflow $59.0 million, net cash increase $12.3 million.
Revenue solely from EsoGuard tests rose $0.4 million YoY to $4.7 million, attributed to expanded commercialization channels including Lucid Test Centers, mobile units, #CheckYourFoodTube events, and direct employer contracting. No segment breakdowns or geographic mix disclosed; focus remains U.S. market for at-risk GERD patients.
Gross position negative with cost of revenue $6.7 million exceeding $4.7 million revenue, improving slightly YoY from $7.1 million vs $4.3 million due to lower manufacturing ($0.6M decrease) despite higher compensation. Operating losses driven by elevated S&M and G&A from MSA amendments and financing. No explicit margins stated.
Net operating cash use $46.5 million, reflecting $58.0 million net loss adjusted for non-cash items like $7.7 million note fair value change (favorable) and working capital shifts. Investing outflow $197K for equipment. Financing provided $59.0 million via offerings ($27.0M Sept, $16.2M April, $14.9M March) and ATM ($0.3M). Ending cash $34.7 million supports total current assets $37.5 million; current liabilities $28.6 million include $24.0M notes. Equity $10.9M after preferred stock $54.3M and accumulated deficit -$274.3M.
Management highlights Medicare LCD reconsideration, VA contract at $1,938 Medicare rate, Highmark coverage, NCCN guideline nods, and real-world data from 12,000 patients. Priorities: reimbursement expansion, clinical utility evidence, commercialization scale. Risks: going concern doubt, cash burn, need for funding beyond March 2027, PAVmed reliance.